Drug Development

ViroLogic Broadens Agreement With Roche and Trimeris For Technology Use

Published in Drug Week, November 9th, 2001

ViroLogic, Inc. has signed an expanded agreement with Hoffmann-La Roche, Inc. and Trimeris, Inc. to use ViroLogic's proprietary HIV resistance testing technology in the development of T-20 and T-1249, the first and most advanced members of a new class of antiviral agents known as fusion inhibitors.

Fusion inhibitors are part of a broader class of antiviral agents collectively referred to as entry inhibitors that block binding to or fusion with target cells.

Under the terms of the agreement, Roche and Trimeris will immediately begin using ViroLogic's newly developed proprietary entry inhibitor assays to evaluate their investigational HIV drugs, T-20,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2001-11-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry